Pay in 4 interest-free payments of $7.34 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Summary of Guidelines for Initiation and Titration of Basal Insulin in Patients With Type 2 Diabetes 8,39,56,71 View popup Table 2
Product packaging may vary
Maximus does not recommend, endorse, or make any representation about the efficacy, appropriateness, or suitability of any specific test, products, procedures, treatments, services, opinions, healthcare providers or other information contained herein
licensed doctors assess clinical fit, prescribe Health Canada-approved GLP-1 medications (Ozempic, Wegovy, Mounjaro) for adults at BMI 30+, or 27+ with a comorbidity, and provide ongoing follow-up
for example, Lilly expects to share Phase 3 obesity data on orfoglipron, an oral GLP-1 agonist, and retatrutide, a triple agonist of GLP/GIP/glucagon receptors in 2025 3 Xie, Y., Choi, T., & Al-Aly, Z
